Twice Weekly TP-HDFL for Recurrent or Metastatic Esophageal Cancer
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to find out the response rate of twice weekly
paclitaxel and cisplatin and weekly HDFL in recurrent or metastatic esophageal carcinoma
patients who need palliative Chemotherapy.